Taysha Gene Therapies logo
Taysha Gene Therapies
TSHA | NASDAQ
Chart Builder DCF Calculator
$4.06
-$0.04 (-0.98%)
At close: Nov 16, 2026, 4:00 PM ET
$4.06
$0.00 (0.00%)
After-hours: Nov 16, 2026, 4:10 PM ET

Taysha Gene Therapies Company Profile

Company profile explained

Company Profile

Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.

Key Executives

Name Position
Sean Nolan Chief Executive Officer & Chairman
Kamran Alam Chief Financial Officer & Corporate Secretary
Michael Johannesen Chief Legal Officer & Corporate Secretary
Berge Minassian Chief Medical Advisor of UT Southwestern Gene Therapy Program
Emily McGinnis Chief Patient & External Affairs Officer
Frederick Porter Chief of Staff & Technical Operations Officer
Hayleigh Collins Director of Corporate Communications & Investor Relations
Sean McAuliffe Chief Business Officer
Steven Gray Chief Scientific Advisor of UT Southwestern Gene Therapy Program
Sukumar Nagendran President, Head of Research & Development and Director

Latest SEC Filings

Date Type Title
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 13, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 11, 2026 10-Q Quarterly Report
Aug 11, 2026 8-K Current Report
Jul 10, 2026 4 Filing
Jun 25, 2026 8-K Current Report
Jun 25, 2026 424B5 Filing
Jun 24, 2026 424B5 Filing
Jun 22, 2026 8-K Current Report
Jun 02, 2026 4 Filing
View All SEC Filings ➞
Taysha Gene Therapies
Taysha Gene Therapies logo
Country United States
IPO Date Sep 24, 2020
Industry Biotechnology
Sector Healthcare
Employees 99
CEO Sean Nolan

Contact Details

3000 Pegasus Park Drive Dallas, Texas 75247 United States

Stock Details

Ticker Symbol TSHA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001806310
CUSIP Number 877619106
ISIN Number US8776191061
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.